Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Maintenance in PCNSL with Persistent cfDNA
NCT04401774Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2020
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in primary central nervous system lymphoma (PCNSL), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2020; status: completed.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04401774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401774.